HLS Therapeutics Inc.
HLS.TO
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 42.78% | 36.76% | 35.92% | 37.55% | 35.41% |
| Total Depreciation and Amortization | -0.74% | -3.96% | -10.45% | -19.40% | -24.99% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -54.68% | -20.82% | -8.32% | -40.41% | -41.43% |
| Change in Net Operating Assets | 134.03% | 314.90% | 11.46% | -30.13% | -35.96% |
| Cash from Operations | 85.31% | 114.04% | 62.07% | 3.67% | -14.18% |
| Capital Expenditure | -441.18% | -1,266.67% | -1,056.25% | -656.25% | 20.93% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | 100.00% | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -114.20% | -111.31% | -109.17% | -107.57% | 9,052.70% |
| Cash from Investing | -117.63% | -114.51% | -111.93% | -119.87% | 6,234.03% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -246.26% | -250.46% | -228.76% | -211.78% | -138.94% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -229.21% | -199.83% | -51.86% | 43.41% | 70.14% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -110.94% | -16.54% | -2.43% | 100.00% | 65.24% |
| Cash from Financing | 0.30% | 7.74% | 23.39% | -121.12% | -66.74% |
| Foreign Exchange rate Adjustments | 141.27% | 145.52% | -661.29% | 54.13% | -1,925.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -216.44% | -27.51% | -58.43% | -275.79% | 3.50% |